Company registration number 15017729 (England and Wales)
Merits Health Products UK Limited
Financial Statements
For the period ended 31 December 2024
PAGES FOR FILING WITH REGISTRAR
Merits Health Products UK Limited
Contents
Page
Balance sheet
1
Notes to the financial statements
2 - 7
Merits Health Products UK Limited
Balance Sheet
As at 31 December 2024
31 December 2024
- 1 -
2024
Notes
£
£
Fixed assets
Tangible assets
3
29,943
Current assets
Stocks
101,102
Debtors
4
64,985
Cash at bank and in hand
35,712
201,799
Creditors: amounts falling due within one year
5
(67,606)
Net current assets
134,193
Total assets less current liabilities
164,136
Creditors: amounts falling due after more than one year
6
(399,074)
Net liabilities
(234,938)
Capital and reserves
Called up share capital
100
Profit and loss reserves
(235,038)
Total equity
(234,938)

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 15 April 2025 and are signed on its behalf by:
Andrew Maskery
Director
Company registration number 15017729 (England and Wales)
Merits Health Products UK Limited
Notes to the Financial Statements
For the Period ended 31 December 2024
- 2 -
1
Accounting policies
Company information

Merits Health Products UK Limited is a private company limited by shares incorporated in England and Wales. The registered office is Pendragon House, 65 London Road, St Albans, Herts, AL1 1LJ.

1.1
Reporting period

The reporting period runs from 21 July 2023 to 31 December 2024, exceeding 12 months. This is the first reporting period for the company, and the accounting period end was extended from 31 July 2024 to 31 December 2024 in order to align with the rest of the group for reporting purposes.

1.2
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.3
Going concern

Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future.

 

The parent company, Merits Health Products Co., Ltd has confirmed that it will continue to support the company for at least twelve months from the date of approval of the financial statements. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.4
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Motor vehicles
20% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

Merits Health Products UK Limited
Notes to the Financial Statements (Continued)
For the Period ended 31 December 2024
1
Accounting policies
(Continued)
- 3 -
1.6
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

1.7
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.8
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.9
Financial instruments

The company has elected to apply the provisions of Section 11 and Section 12 of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present fair value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

 

Basic financial liabilities

Basic financial liabilities, which include trade and other payables and bank loans, are initially measured at transaction price and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present fair value of the future receipts discounted at a market rate of interest.

1.10
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.11
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

Merits Health Products UK Limited
Notes to the Financial Statements (Continued)
For the Period ended 31 December 2024
1
Accounting policies
(Continued)
- 4 -
1.12
Retirement benefits

Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided.

1.13
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

2
Employees

The average monthly number of persons (including directors) employed by the company during the period was:

2024
Number
Total
1
3
Tangible fixed assets
Motor vehicles
£
Cost
At 21 July 2023
-
0
Additions
35,932
At 31 December 2024
35,932
Depreciation and impairment
At 21 July 2023
-
0
Depreciation charged in the period
5,989
At 31 December 2024
5,989
Carrying amount
At 31 December 2024
29,943
Merits Health Products UK Limited
Notes to the Financial Statements (Continued)
For the Period ended 31 December 2024
- 5 -
4
Debtors
2024
Amounts falling due within one year:
£
Trade debtors
19,511
Amounts owed by group undertakings
12,809
Other debtors
32,665
64,985
5
Creditors: amounts falling due within one year
2024
£
Trade creditors
514
Amounts owed to group undertakings
41,100
Taxation and social security
6,357
Other creditors
19,635
67,606
6
Creditors: amounts falling due after more than one year
2024
£
Other creditors
399,074

A loan agreement was entered into with the parent company, Merits Health Products Co., Ltd on 20 November 2023. The principal amount of the loan is up to a total amount of $1,000,000 which can be provided in one or multiple payments. The due date is 20 November 2029.

 

The loan is unsecured but is made with full recourse against Merits Heath Products UK Limited and its successors.

 

Interest shall accrue cumulatively, and on the basis of a 360 day year, on the principal amount at the rate equal to the one-year 4%. Interest shall be paid within 8 days following the interest payment date.

7
Audit report information

As the income statement has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006.

The auditor's report is unqualified and includes the following:

Merits Health Products UK Limited
Notes to the Financial Statements (Continued)
For the Period ended 31 December 2024
7
Audit report information
(Continued)
- 6 -
Opinion

In our opinion the financial statements:

Senior Statutory Auditor:
Luke Parker ACA
Statutory Auditor:
Gilberts Chartered Accountants
Date of audit report:
16 April 2025
8
Operating lease commitments

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2024
£
558
Merits Health Products UK Limited
Notes to the Financial Statements (Continued)
For the Period ended 31 December 2024
- 7 -
9
Related party transactions

The company has taken advantage of the exemptions for qualifying subsidiary undertakings not to include details of transactions with other group companies.

10
Parent company

The company's parent undertaking is Merits Health Products Co. Ltd, a company incorporated in Taiwan.

2024-12-312023-07-21falsefalsefalse16 April 2025CCH SoftwareCCH Accounts Production 2024.301No description of principal activityShun-Yuan ChengMichael LaimanAndrew Maskery2025-04-15150177292023-07-212024-12-31150177292024-12-3115017729core:MotorVehicles2024-12-3115017729core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-3115017729core:Non-currentFinancialInstrumentscore:AfterOneYear2024-12-3115017729core:CurrentFinancialInstruments2024-12-3115017729core:ShareCapital2024-12-3115017729core:RetainedEarningsAccumulatedLosses2024-12-3115017729bus:Director32023-07-212024-12-3115017729core:MotorVehicles2023-07-212024-12-3115017729core:MotorVehicles2023-07-2015017729core:WithinOneYear2024-12-3115017729core:Non-currentFinancialInstruments2024-12-3115017729bus:PrivateLimitedCompanyLtd2023-07-212024-12-3115017729bus:SmallCompaniesRegimeForAccounts2023-07-212024-12-3115017729bus:FRS1022023-07-212024-12-3115017729bus:Audited2023-07-212024-12-3115017729bus:Director12023-07-212024-12-3115017729bus:Director22023-07-212024-12-3115017729bus:FullAccounts2023-07-212024-12-31xbrli:purexbrli:sharesiso4217:GBP